Streamlined Treatment of Pulmonary Exacerbations in Pediatrics
NCT06654752
Recruiting
The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.
Gender:
ALL
Ages:
Between 3 years and 18 years
Trial Updated:
07/30/2025
Locations: The Children's Hospital Alabama & University of Alabama at Birmingham, Birmingham, Alabama +32 locations
Conditions: Cystic Fibrosis
Register for Updates
Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS)
NCT04797299
Recruiting
To evaluate whether the combination of clinicopathological factors and the use of the Oncotype DX DCIS score can avoid radiation in women with low risk DCIS who have had breast conserving surgery (BCS)
Gender:
FEMALE
Ages:
46 years and above
Trial Updated:
07/30/2025
Locations: Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta +21 locations
Conditions: DCIS
Register for Updates
AlloSure Lung Assessment and Metagenomics Outcomes Study
NCT05050955
Recruiting
ALAMO is a prospective, multi-center, perspective, registry of patients receiving LungCare™ (AlloSure®-Lung, AlloMap Lung, and HistoMap) for surveillance post-transplant. This study aims to evaluate the diagnostic performance characteristics of AlloSure Lung (dd-cfDNA) to detect a spectrum of rejection (ACR, AMR) and allograft infection (Bacterial, Viral, Fungal, Mycobacterial, Parasitic).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: University of Alabama (UAB), Birmingham, Alabama +21 locations
Conditions: Lung Transplant Infection, Lung Transplant; Complications, Lung Transplant Failure and Rejection
Register for Updates
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153
Recruiting
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participat... Read More
Gender:
ALL
Ages:
Between 55 years and 80 years
Trial Updated:
07/30/2025
Locations: Parkway Medical Center, Birmingham, Alabama +278 locations
Conditions: Alzheimer's Disease
Register for Updates
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
NCT06100744
Recruiting
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. PsA that begins before a patient's 16th birthday is called juvenile PsA (jPsA).This study will evaluate how safe risankizumab is for the treatment of psoriatic arthritis and to assess change in disease symptoms. Risankizumab is being studied for the treatment of jPsA and... Read More
Gender:
ALL
Ages:
Between 5 years and 18 years
Trial Updated:
07/30/2025
Locations: Arkansas Children's Hospital /ID# 258776, Little Rock, Arkansas +27 locations
Conditions: Juvenile Psoriatic Arthritis
Register for Updates
A Registry for People With Lung Cancer
NCT06424327
Recruiting
Participants will complete questionnaires before surgery, between 2 to 4 weeks after surgery, and 6 months after surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Rush University Medical Center (Data collection only), Chicago, Illinois +9 locations
Conditions: Lung Cancer, Lung Cancer Stage I
Register for Updates
Prospective Clinical Assessment Study in Children With Hypochondroplasia
NCT06410976
Recruiting
This is a long-term, multicenter, non-interventional study of children ages 2.5 to \<17 years with hypochondroplasia (HCH).
Gender:
ALL
Ages:
Between 30 months and 16 years
Trial Updated:
07/30/2025
Locations: UCSF Benioff Children's Hospital, Oakland, California +24 locations
Conditions: Hypochondroplasia
Register for Updates
Combined Pulsed Field and Radiofrequency Energy for Ablation of Ventricular Tachycardia
NCT06816368
Recruiting
This will be a single arm study evaluating a new ablation technology for performing catheter ablation of ventricular tachycardia. The technology combines novel pulsed field ablation with radiofrequency ablation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: McGill University Health Centre, Montreal, Quebec +2 locations
Conditions: Ventricular Tachycardia (V-Tach)
Register for Updates
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
NCT06388564
Recruiting
This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with cGVHD.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/30/2025
Locations: Mayo Clinic Hospital, Phoenix, Arizona +69 locations
Conditions: Chronic Graft-versus-host-disease
Register for Updates
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
NCT05681351
Recruiting
The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: LA Universal Research Center, Inc., Los Angeles, California +261 locations
Conditions: Severe Hypertriglyceridemia
Register for Updates
Individualized Fortification of Human Milk for Infants Born ≤ 1250 g (MaxiMoM-InForM)
NCT05308134
Recruiting
Very low birth weight infants have increased nutritional needs. Extra nutrients are added to their human milk feeds to help improve their nutritional status, growth and neurodevelopment. Standard fortification of human milk is routine in most neonatal units in North America, but despite the added nutrients, infants are often discharged from hospitals with poor growth, and their neurodevelopment remains suboptimal. Two individualized fortification methods, target and BUN adjustable, have been pro... Read More
Gender:
ALL
Ages:
21 days and below
Trial Updated:
07/30/2025
Locations: University of Alberta, Edmonton, Alberta +19 locations
Conditions: Very Low Birth Weight Infant
Register for Updates
Non-invasive Ventilation and Dexmedetomidine in Critically Ill Adults
NCT06259565
Recruiting
Non-Invasive ventilation (NIV) is a life saving intervention for patients with acute respiratory failure (ARF). Some patients are not able to tolerate the NIV intervention and ultimately fail, requiring the use of invasive mechanical ventilation (IMV) and intubation. Sedation may improve a patient's NIV tolerance. However, this practice has not been adopted by intensivists as the risk of over-sedation resulting in respiratory depression, inability to protect the airway, and inadvertent need for... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Fraser Health Authority, Surrey, British Columbia +5 locations
Conditions: Non-Invasive Ventilation
Register for Updates